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Background: Malignancy-associated spinal cord compression is generally treated by surgical decompression,
radiotherapy or a combination of both. Since diffuse large B-cell lymphoma (DLBCL) is highly sensitive to both
chemotherapy and radiotherapy, the role of surgical decompression in the treatment of DLBCL-associated spinal
cord compression remains unclear. We therefore conducted a retrospective review to investigate the impact of
surgical decompression on recovery from neurological deficit caused by DLBCL-associated spinal cord compression
and patients’ overall survival.
Methods: Between March 2001 and September 2011, 497 newly diagnosed DLBCL patients were reviewed, and 11
cases had DLBCL-associated spinal cord compression. Six cases were treated surgically and five cases nonsurgically.
Results: The rates of complete recovery from neurological deficit were 100% (6/6) and 20% (1/5) for patients in the
surgical and nonsurgical groups, respectively (P = 0.015), while the median survival for patients in the surgical and
nonsurgical groups was 48.6 months and 17.8 months, respectively (P = 0.177).
Conclusions: We conclude that surgical decompression can improve recovery from neurological deficit in patients
with DLBCL-associated spinal cord compression, possibly providing these patients a survival benefit.
Keywords: Spinal cord compression, Diffuse large B-cell lymphoma, Decompression surgeryBackground
Malignancy-associated spinal cord compression (MASC)
is a serious oncological emergency of which breast cancer,
prostate cancer, and lung cancer are common etiologies
[1]. In 60 to 80% of MASC patients, the thoracic spine is
involved [2]. Without immediate and appropriate treat-
ment, MASC can result in irreversible neurological deficits* Correspondence: kevinhwl@gmail.com; drteng@vghtc.gov.tw
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reproduction in any medium, provided the orincluding motor and sensory dysfunction, and urine and
stool incontinence. Surgery, radiotherapy, or combinations
of both are treatment options for MASC. Although surgery
followed by palliative radiotherapy can release the com-
pression immediately and facilitate mechanical stabilization
of the spine directly [3], it is performed in only 10 to 15%
of MASC patients. The patients’ poor performance status,
delayed diagnosis, and the risks of the surgery itself may be
reasons why few patients are treated with surgery alone or
in combination. Rather, radiotherapy alone is the most
common treatment for MASC [1]. Chemotherapy has a
limited role in general in MASC treatment because tumor
response usually takes a few weeks, which is too slow to
avoid permanent neurological damage.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(DLBCL) is highly sensitive to chemotherapy. After the
success of a trial conducted by Coiffier [4], a combination
of rituximab with cyclophosphamide, doxorubicin, vincris-
tine, and prednisolone (CHOP) has become the standard
first-line therapy against DLBCL, and largely improves
both treatment response and outcome in patients with this
disease [5]. For those who have only localized disease or
are unable to tolerate systemic chemotherapy, radiother-
apy is an effective alternative treatment. As DLBCL usu-
ally responds to chemotherapy within days, chemotherapy
may be able to replace decompression surgery in DLBCL
patients who have MASC. However, a study conducted by
Peng and colleagues showed a negative impact of decom-
pression surgery on survival in patients with primary
spinal lymphoma complicated by spinal cord compression
[6]. Owing to a lack of statistical power in that study, it re-
mains unclear whether surgical decompression can benefit
DLBCL patients with MASC.
The aims of this study were to compare the rates of
complete recovery from neurological deficit and overall
survival time between patients who received surgical de-
compression and those who did not. We also compared
the overall survival time between patients who experi-
enced complete restoration of their neurological deficit
and those who experienced partial restoration in order
to determine whether a better neurological recovery
could translate into a better overall survival.
Methods
Patients
A retrospective chart review of patients treated in the
Taichung Veterans General Hospital, Taiwan, between
March 2001 and September 2011 was performed after
approval by the institution review board. A total of 497
consecutive cases of newly diagnosed DLBCL were iden-
tified. Of these 497 patients, 11 (2.21%) patients were di-
agnosed with MASC. The diagnosis of DLBCL in these
11 patients was reconfirmed by a pathologist according
to the World Health Organization classifications pro-
posed in 2008 [7]. Six of the patients received surgical
decompression promptly after diagnosis for MASC (sur-
gical group), and the remaining five patients did not re-
ceive surgery (nonsurgical group).
Patient staging
The DLBCL patients with MASC were staged according
to the Ann-Arbor staging system [8]. Briefly, patients
were defined as stage I if they had only a single localized
spinal lesion. Stage II and III diseases were defined as
DLBCL with a single bony site and contiguous or closely
associated lymph nodes, and with distant nodal involve-
ment. DLBCL with diffuse or disseminated involvement
of one or more extra-lymphatic organ, including thosewith primary sites other than the spine, as well as
DLBCL with multiple spinal segment involvement were
defined as stage IV.
Neurological response evaluation
We evaluated the impairment of spinal compression
according to the American Spinal Injury Association im-
pairment scale [9]. When no motor or sensory functions
are preserved in the sacral segments S4 to S5, the com-
pression is classified as scale A. Scale B is assigned when
sensory but not motor function is preserved below the
neurological level and includes the sacral segments S4 to
S5. Scale C is defined as when motor function is pre-
served below the neurological level and more than one-
half of the key muscles below the neurological level have
muscle grade <3, whereas scale D is when motor func-
tion is preserved below the neurological level and at
least one-half of the key muscles below the neurological
level have a muscle grade ≥3. Scale E refers to cases
where motor and sensory functions are normal. In this
study, complete neurological recovery was defined as re-
covery of neurological dysfunction to scale E, regardless
of the initial status.
Performance status and DLBCL treatment response
evaluation
Performance status in each DLBCL patient with MASC
was evaluated according to criteria established by the
Eastern Cooperative Oncology Group [10]. All 11 pa-
tients included in this study received six to eight cycles
of CHOP or CHOP-like regimens as the standard treat-
ment for their underlying DLBCL. The most effective
treatment response to DLBCL in each of these 11 pa-
tients was re-evaluated according to the Response Evalu-
ation Criteria in Solid Tumors [11], and the patient was
categorized as being in complete remission, partial re-
mission, stable disease, or progressive disease.
Statistical analysis
Comparisons of patients’ clinical parameters and overall
survival times between groups were analyzed using the
Mann–Whitney U test or Fisher’s exact test where appro-
priate. A difference is considered significant if P <0.05. All
statistical analyses were carried out using SPSS software,
version 11.5 (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The clinical characteristics of the 11 patients reviewed in
this study are summarized in Table 1. Our cohort
consisted of three men and eight women, with a mean
age of 51.6 years (range: 22 to 75 years). The median
follow-up of this study was 1,040 days (range: 211 to
2,885 days). The most commonly involved segment was
Table 1 Characteristics of patients with diffuse large B-cell lymphoma-associated spinal cord compression
Patient Sex Age
(years)









ASIA scale IPI Initial
management
NR DR
Pre Tx Post Tx
Surgical group (n = 6)
1 F 75 1 L Back pain 3 1 236 No D E Low DS CR CR
2 M 33 1 T Paraplegia 1 2 381 No A E L-I DS CR CR
3 F 44 4 T Paraplegia 2 2 437 No A E H-I DS CR CR
4 F 22 4 T Urine retention 1 2 310 Yes C E H-I DS CR CR
5 F 40 4 T Low limb weakness 7 2 253 Yes C E High DS CR PR
6 F 58 1 L Low limb weakness 7 1 188 No C E Low DS CR CR
Nonsurgical group (n = 5)
7 M 63 1 T Back pain 4 2 237 No C D L-I CT PR CR
8 F 53 4 L, S Low limb weakness 16 3 381 Yes B D H-I RT PR CR
9 F 73 4 T, L Urine retention 1 3 1,021 Yes A E High CT CR PR
10 F 54 4 S Low limb weakness 3 2 223 Yes B D H-I CT PR PR
11 M 53 4 T, S Back pain 30 3 304 Yes A B High CT PR PR
M, male; F, female; T, thoracic spine; L, lumbar spine; S, sacral spine; S/S, symptoms and signs; Tx, treatment; PS, performance status; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; ASIA,
American Spinal Injury Association; IPI, International Prognostic Index; L-I, low-intermediate; H-I, high-intermediate DS, decompression surgery; CT, chemotherapy; RT, radiotherapy; NR, neurological response; CR,
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Lower limb weakness and back pain were the most fre-
quent clinical presentations, occurring in seven of the 11
patients. Of the remaining four patients, two initially
presented with paraplegia while two had urine retention.
According to the Ann-Arbor staging system, four of
the 11 patients were classified as having stage I DLBCL,
while it was stage IV in the other seven patients. No pa-
tients were found to have stage II or III disease. Regard-
ing the international prognostic index classification [12],
seven of the 11 patients in our cohort were in a high-
intermediate or high risk group, and four of them were
in a low or low-intermediate risk group.
Patients who received surgical decompression had a
higher probability of achieving complete neurological
recovery
To investigate whether surgical decompression could pro-
vide DLBCL patients who had MASC with improved
neurological recovery, we compared the complete neuro-
logical deficit recovery rate between patients in the surgical
and nonsurgical groups. The clinical characteristics of the
patients in the surgical and nonsurgical groups are shown
in Table 2. Briefly, the age, gender, performance status,
serum lactate dehydrogenase, extra-nodal involvement,
stages, and international prognostic index classification
were not significantly different between the two groups.
In our study, seven of the 11 patients (63.6%) completely
recovered from their neurological deficit. Further analysis
showed that all patients in the surgical group (n = 6)
achieved complete neurological deficit recovery. However,
only one of the five patients (20.0%) in the nonsurgical
group recovered, suggesting that DLBCL patients with
MASC who received surgical decompression have a higher
probability of completely restoring their neurological def-
icit than those who did not (P = 0.015) (Table 2).
Decompression surgery and complete neurological deficit
recovery might confer a survival benefit
To analyze whether surgical decompression could pro-
vide DLBCL patients with MASC a survival benefit, we
compared the overall survival time in patients between
the surgical and nonsurgical groups. The results showed
that the overall survival time for patients in the surgical
group was 48.6 ± 13.7, while in the nonsurgical group it
was 17.8 ± 3.4 months (mean ± standard error). Although
not statistically significant (P = 0.177), patients in the
surgical group also demonstrated a trend towards super-
ior overall survival when compared with those in the
nonsurgical group (Table 2).
To determine whether the trend towards improved
overall survival in the surgical group was due to superior
recovery from the neurological deficit, we compared the
overall survival time between patients in whom theneurological function was completely restored with those
in whom it was only partially restored (Table 3). Our re-
sults demonstrate that the median overall survival times
for patients with complete and partial neurological recov-
ery were 43.8 ± 12.5 and 19.1 ± 4.1 months (mean ± stand-
ard error), respectively. While patients with complete
recovery showed a trend toward a better overall survival
time than those with partial neurological recovery, our
findings were not statistically significant (P = 0.412).
Discussion
MASC is a rare clinical scenario, occurring in only 0.1
to 3.3% of patients with non-Hodgkin’s lymphoma [13].
In our cohort, MASC was found to occur in 2.21% of
patients with DLBCL. Moreover, two patients (Patients 8
and 11) in our cohort did not receive any treatment until
2 weeks after the neurological deficit occurred. Since
DLBCL is a malignancy with rapid tumor proliferation,
spinal cord compression may occur within weeks of the
onset of MASC. Early and correct diagnosis is therefore
an important issue in DLBCL patients with MASC, and
magnetic resonance imaging, which has an accuracy of
95% (sensitivity 93%, specificity 97%) [14], should be
performed early and correctly when DLBCL patients have
any symptoms or signs associated with spinal compression.
To further understand whether surgical decompres-
sion was the best treatment for complete restoration of
neurological function in DLBCL patients with MASC,
we compared the complete neurological deficit recovery
rate between patients who received surgical decompres-
sion and those who did not. Results showed that all of
the patients who received surgical decompression had
complete abrogation of their neurological dysfunction
(100%, 6/6). On the contrary, only 20.0% (1/5) of the pa-
tients who did not receive surgical decompression recov-
ered. These data suggest that even though DLBCL is
highly sensitive to both chemotherapy [15] and radio-
therapy [16], immediate surgical decompression was the
cornerstone for improving neurological deficit in DLBCL
patients with MASC. Delayed treatment for patients in
the nonsurgical group in our cohort, however, could be
one of the factors affecting this result. Although it was
not statistically significant, patients who received surgi-
cal decompression seemed to have a shorter time from
symptom onset to spinal compression treatment than
those who received nonsurgical intervention (3.5 days
vs. 10.8 days; Table 2). Unfortunately, this delay is un-
avoidable because pathological proof always takes time.
In addition, the pretreatment ASIA scores in patients who
did not receive surgical intervention seemed worse, which
could be another possibility responsible for the superior
neurological deficit recovery in patients who received im-
mediate surgical decompression. Because one of the five
patients in the nonsurgical group exhibited complete
Table 2 Comparison of patients’ clinical characteristics in the surgical and nonsurgical groups
Characteristic Surgical group (n = 6) Nonsurgical group (n = 5) P value
Age (years) 45.3 ± 7.7 59.2 ± 3.9 0.247a
Gender 0.545b
Male 1 (16.7%) 2 (40.0%)
Female 5 (83.3%) 3 (60.0%)
Time from symptoms and signs to treatment (days) 3.5 ± 1.1 10.8 ± 5.5 0.329a
Performance status (ECOG) 0.455b
< 2 2 (33.3%) 0 (0.0%)
≥ 2 4 (66.7%) 5 (100.0%)
Lactate dehydrogenase (IU/l) 300.8 ± 38.4 433.2 ± 149.6 0.792a
Extra-nodal involvement >1 site 0.242b
Yes 2 (33.3%) 4 (80.0%)
No 4 (66.7%) 1 (20.0%)
Stage 0.545b
1 3 (50.0%) 1 (20.0%)
4 3 (50.0%) 4 (80.0%)
International Prognostic Index score 0.545b
Low/low-intermediate 3 (50.0%) 1 (20.0%)
High/high-intermediate 3 (50.0%) 4 (80.0%)
Neurological deficit recovery 0.015b
Complete 6 (100.0%) 1 (20.0%)
Partial 0 (0.0%) 4 (80.0%)
Overall survival (months) 48.6 ± 13.7 17.8 ± 3.4 0.177a
Data presented as mean ± standard error of the mean or number (percentage). ECOG, Eastern Cooperative Oncology Group. aMann–Whitney U test. bFisher’s
exact test.
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mine whether surgical decompression should be applied
to all DLBCL patients with spinal cord compression.
One factor that may provide some clues for the assess-
ment of the utility of surgical decompression is the spine
instability neoplastic score proposed by the Spine Oncol-
ogy Study Group. These scores were established through
systemic reviews to determine which patients harbor
high risk of spinal instability and are in need of surgical
treatment [17]. In this classification system, six compo-
nents of spinal instability – including spine location,
mechanical pain, bone lesion quality, spinal alignment,
vertebral body collapse, and posterolateral involvement
of spinal elements – are used in the risk score calcula-
tion. Patients with a score ≥7 are considered candidates
for surgical intervention. Because this scoring system
was initially established for MASC resulting from solid
malignancies, such as cancers of the breast, prostate,
and lung, its application to DLBCL patients with spinal
cord compression remains uncertain and further valid-
ation is needed. However, this question will not be an-
swered until more studies examining DLBCL-associated
spinal cord compression in larger cohorts are available.Since patients receiving surgical decompression had a
better chance to completely abrogate their neurological def-
icit, we further investigated whether surgical decompres-
sion could have an additional positive impact on patient
survival. Our results suggest that surgical decompression
may result in superior overall survival of DLBCL patients
with spinal compression, even though statistical signifi-
cance was lacking. This result is in contrast to the findings
of a study conducted by Peng and colleagues that showed
the 5-year overall survival rates for patients with primary
non-Hodgkin's lymphoma of the spine with neurological
compression in surgical and nonsurgical groups were
60% and 100%, respectively [6]. More well-designed
clinical trials will therefore be required to clarify this
controversial conclusion.
To strengthen our conclusion that surgical decom-
pression provided patients of DLBCL-associated spinal
cord compression with an improved chance of survival
by eliminating the neurological deficit, we analyzed the
impact of complete recovery from neurological deficit
on these patients’ survival. Our data showed that even
though statistical significance could not be reached,
there was an obvious trend toward better overall survival
Table 3 Comparison of patients’ clinical characteristics in the complete and partial neurological deficit recovery groups
Characteristics Complete neurological deficit
recovery (n = 7)
Partial neurologic deficit
recovery (n = 4)
P value
Age (years) 49.1 ± 7.5 55.8 ± 2.4 0.648a
Gender 0.491b
Male 1 (14.3%) 2 (50.0%)
Female 6 (85.7%) 2 (50.0%)
Time from symptoms and signs to treatment (days) 5.0 ± 1.8 13.3 ± 6.3 0.164a
Performance status (ECOG) 0.491b
< 2 2 (28.6%) 0 (0.0%)
≥2 5 (71.4%) 4 (100.0%)
Lactate dehydrogenase (IU/l) 297.9 ± 32.6 286.3 ± 36.2 0.788a
Extra-nodal involvement >1 site 0.545b
Yes 3 (42.9%) 3 (75.0%)
No 4 (57.1%) 1 (25.0%)
Stage 1.000b
1 3 (42.9%) 1 (25.0%)
4 4 (57.1%) 3 (75.0%)
International Prognostic Index score 1.000b
Low/low-intermediate 3 (42.9%) 1 (25.0%)
High/high-intermediate 4 (57.1%) 3 (75.0%)
Overall survival (months) 43.8 ± 12.5 19.1 ± 4.1 0.412a
Data presented as mean ± standard error of the mean or number (percentage). ECOG, Eastern Cooperative Oncology Group. aMann–Whitney U test. bFisher’s
exact test.
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who completely abrogated their neurological deficit. From
this result, we suggested that decreases in comorbidities
associated with spinal cord compression, such as cardio-
pulmonary dysfunction [18], poor infection control [19],
and psychological problems [20], could play an important
role in the superior overall survival observed in patients
with DLBCL-associated spinal cord compression who re-
ceived surgical decompression.
Another issue surrounding the prediction of prognosis
in DLBCL-associated MASC patients was raised by this
study. Currently, the International Prognosis Index –
which takes into account age, disease stage, extent of
extra-nodal involvement, performance status, and serum
lactate dehydrogenase level [12] – is widely used for risk
classification in patients with DLBCL. However, Inter-
national Prognosis Index scores could not precisely pre-
dict survival in our cohort (data not shown), possibly
due to an invalid staging system and performance status
evaluation. According to the Ann-Arbor staging system,
the disease was classified as stage IV if the spine was not
the primary site. However, it was difficult to distinguish
primary spinal DLBCL from DLBCL with spinal involve-
ment but other primary sites. In addition, patients with
the involvement of multiple spinal segments were also
defined as stage IV, regardless of whether there was anabsence of closely associated or distant lymph node in-
volvement. According to these staging criteria, only stage
I and stage IV disease were present in our cohort. More-
over, the evaluation of performance status in patients
with DLBCL-associated spinal cord compression may be
imprecise. According to Eastern Cooperative Oncology
Group performance status evaluation criteria, a patient
is classified as grade 3 if they are capable of only limited
self-care, and are confined to a bed or chair for more
than 50% of waking hours. However, the neurological
deficit of DLBCL-associated spinal cord compression
patients could cause them to be bed-ridden at diagnosis,
resulting in an underestimated performance status. This
underestimated performance status can further lead to
an imprecise International Prognosis Index score, caus-
ing it to be inferior to the true score. To compensate for
the effects of invalid staging system and performance
status evaluation, a modified prognostic prediction sys-
tem specific to patients with DLBCL-associated spinal
cord compression should be developed.
The major limitations of this study were the small
study cohort and its retrospective nature. Because of the
small cohort, we were unable to validate the spine
instability neoplastic score specific to DLBCL patients
with MASC. We were also unable to establish a revised
International Prognosis Index score to identify the risk
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patients. In addition, although six to eight cycles of CHOP
or CHOP-like regimens were sequentially delivered to all
the patients in our cohort as the standard treatment for
DLBCL, the roles of rituximab and radiotherapy on patients
in our cohort were not evaluated due to the retrospective
nature of this study.
Conclusion
In summary, our results have demonstrated that surgical
decompression improves recovery from neurological deficit,
and may potentially provide a survival benefit in patients
with DLBCL-associated spinal cord compression. Thera-
peutic modalities for improving the treatment of DLBCL,
such as the introduction of rituximab [21] and high-dose
chemotherapy followed by autologous hematopoietic stem
cell transplantation [22], may further improve the out-
come of these patients. Well-designed randomized control
studies with larger cohorts are urgently warranted to an-
swer these questions.
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